| OEM | OEM Services Provided |
| Feature | Good stability |
| Classification | Chemicals |
| Advantage | Professional, Fast Delivery, Customizable | Samples | Apply for free，Contact Export Director now ↓ |
Etodolac is a new generation of COX-2 highly selective nonsteroidal anti-inflammatory drug. This product belongs to weak acid drug, which is in molecular form under low pH value, which is conducive to drug absorption.,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It is commonly prescribed for osteoarthritis, rheumatoid arthritis, and acute pain management. Below are five detailed tables summarizing its chemical properties, pharmacokinetics, therapeutic uses, safety profile, and drug interactions.
| Property | Specification | Test Method |
|---|---|---|
| Chemical name | (±)-1.8-Diethyl-1.3.4.9-tetrahydropyrano[3.4-b]indole-1-acetic acid | IUPAC nomenclature |
| Molecular formula | C<sub>17</sub>H<sub>21</sub>NO<sub>3</sub> | Chemical analysis |
| Molecular weight | 287.36 g/mol | Mass spectrometry |
| Melting point | 145–148°C | DSC/TGA analysis |
| Solubility in water | Practically insoluble | USP solubility test |
| Parameter | Value/Range | Remarks |
|---|---|---|
| Bioavailability | ~80% (oral) | High absorption |
| Protein binding | >99% | Highly bound to albumin |
| Metabolism | Hepatic (CYP3A4. CYP2C9) | Forms inactive metabolites |
| Half-life (t<sub>½</sub>) | 6–7 hours (immediate-release) | Prolonged in elderly |
| Excretion | Urine (73%), feces (17%) | Mostly as metabolites |
| Application | Adult Dose (Oral) | Special Considerations |
|---|---|---|
| Osteoarthritis | 600–1200 mg/day (divided doses) | Max 1200 mg/day |
| Rheumatoid arthritis | 400–1000 mg/day (divided doses) | Adjust for renal impairment |
| Acute pain | 200–400 mg every 6–8 hrs | Short-term use only |
| Maximum daily dose | 1200 mg (chronic use) | Lower in elderly patients |
| Effect | Risk Level | Management |
|---|---|---|
| Gastrointestinal ulcers | Moderate (dose-dependent) | Use with PPI if high risk |
| Cardiovascular risk | Moderate (long-term use) | Avoid in CAD patients |
| Renal impairment | Moderate (in CKD patients) | Monitor creatinine |
| Hepatotoxicity | Rare | Discontinue if LFTs elevate |
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Warfarin | ↑ Bleeding risk | Monitor INR closely |
| Diuretics (e.g., furosemide) | ↓ Diuretic efficacy | Avoid concurrent use |
| ACE inhibitors (e.g., lisinopril) | ↓ Antihypertensive effect | Monitor BP |
| Lithium | ↑ Lithium toxicity | Avoid or monitor levels |
Etodolac is an effective NSAID for chronic inflammatory conditions and acute pain, but its use requires caution in patients with cardiovascular, renal, or gastrointestinal risks. Proper dosing and monitoring are essential to minimize adverse effects.
Declaration: The products displayed on this website are intended exclusively for industrial applications or scientific research. They are not intended for medical, pharmaceutical, or food use. In accordance with applicable laws and regulations, purchasing organizations must hold valid qualifications and approvals.
For help with solutions customized to your business needs, contact Export Director now.
With 30+ years of experience and We firmly believe that product quality is the basis of cooperation.
Chat Now
TEl
+86-21-6420 0566
